Octapharma AG - Home
EN: Navigation mit Access Keys
[Alt + 0] - Startseite
[Alt + 1] - Navigation
[Alt + 2] - Inhalt
[Alt + 3] - Kontakt
[Alt + 4] - Sitemap
[Alt + 5] - Suche
EN: Hauptnavigation
About Octapharma
Corporate Profile
Products & Therapies
Safety & Quality
Product Development
News & Events
Career
Healthcare Professionals
Products & Therapies
Product Development
Safety & Quality
8 Questions
Patients
Our Commitment
Disease & Therapies
Plasma Donations
8 Questions
Contact
Type your search here...
Octapharma news & events
Octapharma submits marketing authorization application (MAA) to the EMA for the first truly human recombinant coagulation factor VIII from a human cell line.
31.05.2013
more
Octapharma Leading Corporate Sponsor of Save One Life
22.05.2013
more
New therapeutic option for immunocompromised patients in Canada
05.04.2013
more
Meet Octapharma
Octapharma's Corporate Video
As a world-wide provider of human proteins as treatments in immunotherapy, haematology, and intensive care and emergency medicine, Octapharma is constantly investing in the renovation and modernisation of our plants.
Wolfgang Marguerre Chairman of the Board
As a world-wide provider of human proteins as treatments in immunotherapy, haematology, and intensive care and emergency medicine, Octapharma is constantly investing in the renovation and modernisation of our plants.